Osteopontin expression correlates with melanoma invasion

Journal of Investigative Dermatology

Volumn 124, Issue 5, 2005, Pages 1044-1052

  Zhou, Youwen ^a   Dai, Derek L ^a   Martinka, Magdalena ^a   Su, Mingwan ^a   Zhang, Yi ^a   Campos, Eric I ^a   Dorocicz, Irene ^a   Tang, Liren ^a   Huntsman, David ^a   Nelson, Colleen ^a   Ho, Vincent ^a   Li, Gang ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

DNA microarray; Melanoma invasion; Osteopontin; RNA interference; Tissue microarray

Indexed keywords

OSTEOPONTIN; RNA;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SKIN BIOPSY;

EID: 20944443085     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0022-202X.2005.23680.x     Document Type: Article

References (61)

1. Adwan H, Bauerle TJ, Berger MR: Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells. Cancer Gene Ther 11:109-120, 2004
2. Angelucci A, Festuccia C, D'Andrea G, Teti A, Bologna M: Osteopontin modulates prostate carcinoma invasive capacity through RGD-dependent upregulation of plasminogen activators. Biol Chem 383:229-234, 2002
3. Behrend EI, Craig AM, Wilson SM, Denhardt DT, Chambers AF: Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res 54:832-837, 1994
4. Behrend EI, Craig AM, Wilson SM, Denhardt DT, Chambers AF: Expression of antisense osteopontin RNA in metastatic mouse fibroblasts is associated with reduced malignancy. Ann NY Acad Sci 760:299-301, 1995
5. Bittner M, Meltzer P, Chen Y, et al: Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406:536-540, 2000
6. Brem R, Hildebrandt T, Jarsch M, Van Muijen GN, Weidle U: H. Identification of metastasis-associated genes by transcriptional profiling of a metastasizing versus a non-metastasizing human melanoma cell line. Anticancer Res 21:1731-1740, 2001
7. Brown LF, Papadopoulos-Sergiou A, Berse B, et al: Osteopontin expression and distribution in human carcinomas. Am J Pathol 145:610-623, 1994
8. Byers HR, Etoh T, Doherty JR, Sober AJ, Mihm MC Jr: Cell migration and actin organization in cultured human primary, recurrent cutaneous and metastatic melanoma. Time-lapse and image analysis. Am J Pathol 139:423-435, 1991
9. Carlinfante G, Vassilioul D, Svensson O, Wendel M, Heinegard D, Andersson G: Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma. Clin Exp Metastasis 20:437-444, 2003
10. Chambers AF, Wilson SM, Kerkvliet N, O'Malley FP, Harris JF, Casson AG: Osteopontin expression in lung cancer. Lung Cancer 15:311-323, 1996
11. Chang PL, Cao M, Hicks P: Osteopontin induction is required for tumour promoter-induced transformation of preneoplastic mouse cells. Carcinogenesis 24:1749-1758, 2003
12. Chellaiah M, Fitzgerald C, Filardo EJ, Cheresh DA, Hruska KA: Osteopontin activation of c-src in human melanoma cells requires the cytoplasmic domain of the integrin alpha v-subunit. Endocrinology 137:2432-2440, 1996
13. Clark WH Jr, Elder DE, Guerry DT, et al: Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 81:1893-1904, 1989
14. Clark EA, Golub TR, Lander ES, Hynes RO: Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406:532-535, 2000
15. Dai DL, Makretsov N, Campos EI, et al: Increased expression of integrin-linked kinase is correlated with melanoma progression and poor patient survival. Clin Cancer Res 9:4409-4414, 2003
16. Das R, Mahabeleshwar LM, Kundu GC: Osteopontin stimulates cell motility and nuclear factor kappa B-mediated secretion of urokinase type plasminogen activator through phosphatydylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J Biol Chem 278:28593-28606, 2003
17. Denhardt DT, Giachelli CM, Rittling SR: Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol 41:723-749, 2001
18. Denhardt DT, Quo X: Osteopontin: A protein with diverse functions. FASEB J 7:1475-1482, 1993
19. Ding Q, Stewart J Jr, Prince CW, et al: Promotion of malignant astrocytoma cell migration by osteopontin expressed in the normal brain: Differences in integrin signaling during cell adhesion to osteopontin versus vitronectin. Cancer Res 62:5336-5343, 2002
20. Faccio R, Grano M, Colucci S, Zallone AZ, Quaranta V, Pelletier AJ: Activation of alpha v/beta3 integrin on human osteoclast-like cells stimulates adhesion and migration in response to osteopontin. Biochem Biophys Res Commun 249:522-525, 1998
21. Gardner HA, Berse B, Senger DR: Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts. Oncogene 9:2321-2326, 1994
22. Geissinger E, Weisser C, Fisher P, Schartl M, Wellbrock C: Autocrine stimulation by osteopontin contributes to anti-apoptotic signaling of melanocytes in dermal collagen. Cancer Res 62:4820-4828, 2002
23. Gilchrest BA, Vrabel MA, Flynn E, Szabo G: Selective cultivation of human melanocytes from newborn and adult epidermis. J Invest Dermatol 83:370-376, 1984
24. Gotoh M, Sakamoto M, Kanetaka K, Chuuma M, Hirohashi S: Overexpression of osteopontin in hepatocellular carcinoma. Pathol Int 52:19-24, 2002
25. Green RJ, Schuchter LM: Systemic treatment of metastatic melanoma with chemotherapy. Hematol Oncol Clin North Am 12:863-875, 1998
26. Hendrix MJ, Seftor EA, Hess AR, Seftor RE: Molecular plasticity of human melanoma cells. Oncogene 22:3070-3075, 2003
27. Hess AR, Seftor EA, Seftor RE, Hendrix MJ: Phosphoinositide 3-kinase regulates membrane Type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry. Cancer Res 63:4757-4762, 2003
28. Heymann D, Blanchard F, Raher S, De Groote D, Godard A: Modulation of LIF expression in human melanoma cells by oncostatin M. Immunol Lett 46:245-251, 1995
29. Hsu MY, Shih DT, Meier FE, et al: Adenoviral gene transfer of β3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. Am J Pathol 153:1435-1442, 1998
30. Hu DD, Lin EC, Kovach NL, Hoyer JR, Smith JW: A biochemical characterization of the binding of osteopontin to integrins alpha v beta 1 and alpha v beta 5. J Biol Chem 270:26232-26238, 1995
31. Kondo Y, Ohsawa N: Production of human alpha 1-antichymotrypsin-like protein by a human malignant melanoma transplanted into nude mice. Cancer Res 42:1549-1554, 1982
32. Leali D, Dell'Era P, Stabile H, et al: Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in angiogenesis. J Immunol 171:1085-1093, 2003
33. Le QT, Sutphin PD, Raychaudhuri S, et al: Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 9:59-67, 2003
34. Leader M, Patel J, Collins M, Henry K: Anti-alpha 1-antichymotrypsin staining of 194 sarcomas, 38 carcinomas, and 17 malignant melanomas-its lack of specificity as a tumour marker. Am J Surg Pathol 11:133-139, 1987
35. Li G, Bush JA, Ho VC: p53-dependent apoptosis in melanoma cells after treatment with camptothecin. J Invest Dermatol 114:514-519, 2000
36. Li Y, Mc Clay EF: Systemic chemotherapy for the treatment of metastatic melanoma. Semin Oncol 29:413-426, 2002
37. Liu YK, Uemura T, Nemoto A, Yabe T, Fujii N, Ushida T, Tateishi T: Osteopontin involvement in integrin-mediated cell signaling and regulation of expression of alkaline phosphatase during early differentiation of UMR cells. FEBS Lett 420:112-116, 1997
38. Mc Clay EF, Mc Clay ME: Systemic chemotherapy for the treatment of metastatic melanoma. Semin Oncol 23:744-753, 1996
39. Nemoto H, Rittling SR, Yoshitake H, et al: Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues. J Bone Miner Res 16:652-659, 2001
40. Oates AJ, Barraclough R, Rudland PS: The role of osteopontin in tumorigenesis and metastasis. Invasion Metastasis 17:1-15, 1997
41. Paglia D, Oran A, Lu C, Kerbel RS, Sauder DN, McKenzie RC: Expression of leukemia inhibitory factor and interleukin-11 by human melanoma cell lines: LIF, IL-6, and IL-11 are not co-regulated. J Interferon Cytokine Res 15:455-460, 1995
42. Pan HW, Ou YH, Peng SY, et al: Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 98:119-127, 2003
43. Philip S, Bulbule A, Kundu GC: Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-κ B-medialed induction of membrane type I matrix metalloproteinase in murine melanoma cells. J Biol Chem 276:44926-44935, 2001
44. Rigel DS: Malignant melanoma: Perspectives on incidence and its effects on awareness, diagnosis, and treatment. CA Cancer J Clin 46:195-198, 1996
45. Rigel DS: Malignant melanoma: Incidence issues and their effect on diagnosis and treatment in the 1990s. Mayo Clin Proc 72:367-371, 1997
46. Rigel DS, Friedman RJ, Kopf AW, Robinson JK, Amonette R: A. Melanoma incidence: If it quacks like a duck. Arch Dermatol 133:656-659, 1997
47. Ritting SR, Chambers AF: Role of osteopontin in tumour progression. Br J Cancer 90:1877-1881, 2004
48. Rudland PS, Platt-Higgins A, El Tanani M, et al: Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 62:3417-3427, 2002
49. 3 integrin-induced endothelial cell survival. J Cell Biol 141:1083-1093, 1998
50. Seykora JT, Jih D, Elenitsas R, Horng WH, Elder DE: Gene expression profiling of melanocytic lesions. Am J Dermatopathol 25:6-11, 2003
51. Straume O, Akslen LA: Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression. Am J Pathol 160:1009-1019, 2002
52. Thalmann GN, Sikes RA, Devoll RE, et al: Osteopontin: possible role in prostate cancer progression. Clin Cancer Res 5:2271-2277, 1999
53. Tuck AB, Arsenault DM, O'Malley FP, Hota C, Ling MC, Wilson SM, Chambers AF: Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 18:4237-4246, 1999
54. Tuck AB, Elliott BE, Hota C, Tremblay E, Chambers AF: Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). J Cell Biochem 78:465-475, 2000
55. Wang E, Miller LD, Ohnmacht GA, et al: Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 62:3581-3586, 2002
56. Wang-Rodriguez J, Urquidi V, Rivard A, Goodison S: Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status. Breast Cancer Res 5:R136-R143, 2003
57. Weeraratna AT, Jiang Y, Hostetter G, Rosenblatt K, Duray P, Bittner M, Trent JM: Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1:279-288, 2002
58. Wu Y, Denhardt DT, Ritting SR: Osteopontin is required for full expression of the transformed phenotype by the ras oncogene. Br J Cancer 83:156-163, 2000
59. Zheng DQ, Woodard AS, Tallini G, Languino LR: Substrate specificity of alpha(v)beta(3) integrin-mediated cell migration and phosphatidylinositol 3-kinase/AKT pathway activation. J Biol Chem 275:24565-24574, 2000
60. Zohar R, Suzuki N, Suzuki K, Arora P, Glogauer M, McCulloch CA, Sodek J: Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration. J Cell Physiol 184:118-130, 2000
61. Yeatman TJ, Chambers AF: Osteopontin and colon cancer progression. Clin Exp Metastasis 20:85-90, 2003